Business Wire

Bona Releases 2021 Sustainability Report

5.4.2022 10:15:00 EEST | Business Wire | Press release

Share

Bona ®, a global, sustainably-driven company that supplies products for installing, renovating, maintaining and restoring premium floors, today released the results of its 2021 Sustainability Report. The report highlights Bona’s most significant sustainability milestones for the year focused on its commitment to betterment for home, health, and humanity.

“Our commitment and responsible approach to the environment, people and society has remained steadfast for more than 100 years,” said Kerstin Lindell, Chair of the Board, Bona AB. “This past year presented some challenges, including supply chain and raw materials shortages, yet Bona stayed flexible and focused. Thanks to our fantastic team, our promise to deliver the best products and systems to our customers never wavered and we continue to identify more sustainable solutions. The ability to quickly shift, work together, and develop products and offerings despite changing market conditions has been key to our success.”

Sustainable development on the agenda

In 2021, Bona made some significant investments in its commitment to a sustainable future. The first was the introduction of an electric truck to Bona’s transportation fleet in Limburg, Germany. The electric truck will contribute to lower nitrogen dioxide levels in the city of Limburg and to global decarbonization. In Sweden, Bona invested in a geothermal system that will provide Bona’s Malmö facility with geothermal energy offsetting 20 percent of the yearly energy use at the facility. Another significant milestone last year was the purchase of 26,000-square-meters of land to build a new facility in Monroe, North Carolina, USA. The project, which will be completed in 2022, supports more efficient operations and increased internal capabilities allowing Bona US to operate in a more environmentally friendly way.

Björn Johansson Global Environmental Manager at Bona, said, “We continue to take important steps forward by increasing our use of renewable energy, smarter materials and packaging that uses less virgin plastic, and exhaustively researching new and better ingredients for our products. While we still have work to do, 2021 was a year where we made good progress.”

Highlights of the year

Bona’s core offering encourages care, maintenance, and renovation of hard flooring surfaces such as wood and resilient rather than replacing these materials thereby safeguarding the earth’s finite resources. In 2021 Bona produced finishes, stains, and sealers to cover more than 43 million square meters of wood flooring, saving a forest area equal to approximately 32 million square meters. By not cutting down the forest, the same number of trees encapsulates 28,917 tonnes of carbon dioxide (CO2), calculated as 9-ton CO by hectare and year.

Also in 2021, Bona initiated the use of 90 percent post-consumer recycled (PCR) material in its microfiber pads designed for the Bona Spray Mop and Bona Microfiber Mop. Aligning to the company’s goal to use less virgin plastic, this shift is helping divert over 217 tons of plastic waste from being incinerated or going to landfills.

In the autumn of last year, Bona received the Safer Choice Partner of the Year Award from the US Environmental Protection Agency (EPA) for its work innovating better ingredients in its floor cleaning solutions. Since becoming a Safer Choice partner in 2020, Bona has certified 13 products, six of which were certified in 2021.

Other key facts

Additional notable facts from Bona’s 2021 Sustainability report include:

  • Five years ago, Bona moved its adhesive product from buckets to a tube packaging called “sausages.” In 2021 Bona reduced its environmental footprint by using sausages rather than buckets and over the past five years Bona has avoided using more than 258,000 buckets which is a carbon savings of 243,281 kg.
  • An innovative ergonomic tool was launched 2021 as a new addition to the Bona FlexiSand Pro System. The Bona ErgoEdge is a machine attachment that allows flooring contractors to achieve smooth, efficient sanding in corners and edges of a floor without kneeling or bending by attaching to an existing, standing machine. This innovation saves time and offers a more ergonomic experience for the contractor all while providing a premium floor sanding experience.
  • In 2021 Bona released several new products all of which were formulated with Bona’s commitment to greener chemistry including amplified formulas of its Bona Hardwood Floor and Bona Hard-Floor cleaning solutions. The formulations are water-based, biodegradable, meet the U.S. EPA product standards, and are Safer Choice Certified.
  • Since 2016, Bona has collaborated with Hand in Hand, a non-governmental organization (NGO) that fights poverty with grassroots entrepreneurship, to increase the quality of life for three villages in India. With the organizations Village Upliftment Program, Bona’s partnership has helped improve living conditions for women and children through education and the creation of new jobs.

About the framework of Bona’s 2021 Sustainability Report

For the fifth year in a row, Bona reported the company's sustainability work in accordance with Swedish law and standards. The 2021 Sustainability Report aligns to the UN Sustainability goals and summarizes the sustainability information in the four areas of environment, social conditions, personnel and respect for human rights and the fight against corruption. View the full report at bona.com/sustainability

About Bona

Bona is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. Bona’s turnover is 3.1bn SEK (EUR 307 million) 2021. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 4 production units and 600 employees. For more visit www.bona.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heather Lindemann | Bona
+1 (800) 872-5515
heather.lindemann@bona.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye